News

InCarda Therapeutics Recruiting for Phase 2 Clinical Trial in PAF

InCarda Therapeutics is currently conducting a Phase 2 clinical trial (INSTANT) in patients with symptomatic paroxysmal atrial fibrillation (PAF). For more information, please refer to the clinicaltrials.gov registration link below. https://www.clinicaltrials.gov/ct2/show/NCT03539302?term=INSTANT&cond=Atrial+Fibrillation&rank=1...

InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation

Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...

InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020

Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF)  Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 San Francisco, CA...

InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020)

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in...

InCarda Therapeutics featured in FierceBiotech News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “What we're doing is a completely new way of...

InCarda Therapeutics featured in Endpoints News

InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “This is especially exciting at a time when more...

InCarda at Biotech Industry Organization’s (BIO) International Conference 2019

June 3-6, 2019 - Philadelphia, PA “Addressing Unmet Need in Cardiovascular Disease” Panel At the 2019 Biotech Industry Organization’s (BIO) International Conference held in June in Philadelphia, InCarda’s CEO, Dr. Grace Colon, was a participant on a panel of distinguished experts entitled “Addressing Unmet Need in Cardiovascular...

InCarda at 2019 Stanford Biodesign New Arrhythmia Technologies Retreat

May 7, 2019 - Palo Alto, CA At the 2019 Stanford Biodesign New Arrhythmia Technologies Retreat, InCarda’s Chief Medical Officer, Dr. Luiz Belardinelli, provided an overview of the pre-clinical and clinical development for InRhythm (flecainide for inhalation). Dr. Bellardinelli explained to the audience of cardiology experts...